Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E
Cells. 2024; 13(19.
PMID: 39404413
PMC: 11475195.
DOI: 10.3390/cells13191650.
Boraschi P, Mazzantini V, Donati F, Coco B, Vianello B, Pinna A
Eur J Radiol Open. 2024; 13:100595.
PMID: 39206437
PMC: 11357777.
DOI: 10.1016/j.ejro.2024.100595.
Harper L, Farver C, Yadav R, Culver D
J Autoimmun. 2024; 149:103288.
PMID: 39084998
PMC: 11791745.
DOI: 10.1016/j.jaut.2024.103288.
Shifman H, Hatchett J, Pai R, Safer R, Gomel R, Vyas M
J Pediatr Gastroenterol Nutr. 2024; 79(4):835-840.
PMID: 38899591
PMC: 11444895.
DOI: 10.1002/jpn3.12287.
Khajehahmadi Z, Nikeghbalian S, Roshanaei G, Mohagheghi S
Arch Iran Med. 2024; 27(1):23-29.
PMID: 38431957
PMC: 10915929.
DOI: 10.34172/aim.2024.04.
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.
Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J
Hepatol Int. 2024; 18(2):299-383.
PMID: 38416312
DOI: 10.1007/s12072-023-10629-3.
Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity.
Maretti-Mira A, Salomon M, Hsu A, Dara L, Golden-Mason L
Front Immunol. 2023; 14:1137034.
PMID: 37063898
PMC: 10098346.
DOI: 10.3389/fimmu.2023.1137034.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
Trauner M, Chung C, Sterling K, Liu X, Lu X, Xu J
BMC Gastroenterol. 2023; 23(1):75.
PMID: 36922785
PMC: 10015541.
DOI: 10.1186/s12876-023-02653-2.
Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review.
Nguyen C, Kline K, Stevenson H, Khan K, Parupudi S
World J Hepatol. 2022; 14(3):495-503.
PMID: 35582290
PMC: 9055190.
DOI: 10.4254/wjh.v14.i3.495.
Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study.
Munoz-Sanchez G, Perez-Isidro A, de Landazuri I, Lopez-Gomez A, Bravo-Gallego L, Garcia-Ormaechea M
Diagnostics (Basel). 2022; 12(3).
PMID: 35328252
PMC: 8947365.
DOI: 10.3390/diagnostics12030697.
Role of liver biopsy in management of liver diseases without hepatic nodules following end of the interferon era: experience of a tertiary referral center.
Ehsan N, Elsabaawy M, Sweed D, Karman E, Abdelsameea E, Mohamed A
Clin Exp Med. 2022; 23(1):97-105.
PMID: 35262836
PMC: 9939494.
DOI: 10.1007/s10238-022-00797-1.
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Saffioti F, Mavroeidis V
World J Gastrointest Oncol. 2021; 13(10):1336-1366.
PMID: 34721770
PMC: 8529934.
DOI: 10.4251/wjgo.v13.i10.1336.
Hepatic sarcoidosis resembling primary sclerosing cholangitis.
Chen Y, Ciobanu C, Mohrmann L
BMJ Case Rep. 2021; 14(9).
PMID: 34493554
PMC: 8424844.
DOI: 10.1136/bcr-2021-243492.
Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.
Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S
Cells. 2021; 10(8).
PMID: 34440687
PMC: 8394127.
DOI: 10.3390/cells10081917.
Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.
Elkilany A, Geisel D, Muller T, Fischer A, Denecke T
Abdom Radiol (NY). 2020; 46(3):979-991.
PMID: 32918576
PMC: 8257540.
DOI: 10.1007/s00261-020-02731-z.
Geoepidemiologic variation in outcomes of primary sclerosing cholangitis.
Mehta T, Weissman S, Fung B, Tabibian J
World J Hepatol. 2020; 12(4):116-124.
PMID: 32685104
PMC: 7336294.
DOI: 10.4254/wjh.v12.i4.116.
Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases.
Meadows V, Kennedy L, Kundu D, Alpini G, Francis H
Front Med (Lausanne). 2020; 7:15.
PMID: 32064266
PMC: 7000431.
DOI: 10.3389/fmed.2020.00015.
Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease.
Suri J, Danford C, Patwardhan V, Bonder A
J Clin Med. 2020; 9(2).
PMID: 31979326
PMC: 7074547.
DOI: 10.3390/jcm9020319.
Biliary endoscopy in the management of primary sclerosing cholangitis and its complications.
Fung B, Tabibian J
Liver Res. 2019; 3(2):106-117.
PMID: 31341699
PMC: 6656407.
DOI: 10.1016/j.livres.2019.03.004.
Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.
Fung B, Lindor K, Tabibian J
World J Gastroenterol. 2019; 25(6):659-671.
PMID: 30783370
PMC: 6378537.
DOI: 10.3748/wjg.v25.i6.659.